Recent Announcements

PhotoPharmics, a clinical-stage medical device company developing photo-neuromodulation therapies...

PhotoPharmics, a clinical-stage medical device company pioneering Photo Neuromodulation for neurodegenerative disease, today announced it has surpassed its enrollment target with 350 participants in its pivotal, Phase 3 Light for PD clinical trial evaluating the Celeste® device for people living with Parkinson’s disease.

“Exceeding our target and closing enrollment is a remarkable milestone for the Parkinson’s community,” said Kent Savage, Chief Executive Officer of PhotoPharmics. “We’re proving that rigorous science can be both patient-centered and home-based. We’re deeply grateful to our investigators, study teams, and especially our participants and their families, whose courage and commitment make this work possible.”

Attendees invited to Booth #732 for pivotal trial updates and to discuss unmet needs in...

Renowned leaders in neurology, movement disorders, and commercialization join to shape Celeste®...